|
|
Commercial Opportunities from an Aging Population: Epidemiology, Market and Pipeline Analysis Across Seven Major IndicationsPublished by: Business Insights Published: Feb. 6, 2004 - 216 Pages Table of ContentsExecutive Summary Quantifying the ‘gray market’ opportunity Acute ischemic stroke Alzheimer’s disease Arthritis Diabetes Male sexual dysfunction Osteoporosis Prostate cancer Chapter 1 Quantifying the ‘gray market’ opportunity Summary Introduction Drivers of gray market growth Demographic trends: an aging population Healthcare needs increase with age The prevalence of chronic diseases is significantly higher among seniors Drugs will be used for longer as life expectancy increases Seniors’ influence on the prescribing process Exploiting increased contact between seniors and physicians Harnessing the power of the web to communicate with seniors Internet use is already promoting patient-physician interaction Meeting seniors’ health information needs Pharmaceutical industry online initiatives targeting seniors – Novartis’ healthandage.com Chapter 2 Acute ischemic stroke Summary Disease overview Epidemiology Market analysis: focus on antithrombotics Activase (alteplase) Pipeline analysis Unmet needs in acute therapy Failure of neuroprotective agents Are antithrombotics the answer? Antithrombotics in development for acute ischemic stroke ReoPro (abciximab) Retavase (reteplase) Chapter 3 Alzheimer’s disease Summary Disease overview Epidemiology Market analysis Aricept (donepezil) Exelon (rivastigmine) Reminyl (galantamine) Ebixa (memantine) Late-stage pipeline analysis Cere (cerebrolysin) COGNIShunt NS-2330 Chapter 4 Arthritis Summary Disease overview Epidemiology Market analysis Celebrex (celecoxib) Vioxx (rofecoxib) Bextra (valdecoxib) Remicade (infliximab) Pipeline analysis Prexige (lumiracoxib) CDP-870 Chapter 5 Diabetes Summary Disease overview Epidemiology Market analysis Class dynamics Sulfonylureas Biguanides Thiazolidinediones Prandial glucose regulators Alfa glucosidase inhibitors Insulins Monotherapy versus combination therapy Leading and new products Avandia (rosiglitazone) Novolin (insulin) Humalog (insulin lispro) Lantus (insulin glargine) Pipeline analysis Exubera (inhaled insulin) AERx insulin Diabetes Management System (inhaled insulin) Oralin (transoral insulin) HIM2 (oral insulin) Chapter 6 Male sexual dysfunction Summary Disease overview Loss of libido Erectile dysfunction Priapism Peyronie’s disease Premature and delayed ejaculation Epidemiology Market analysis Viagra (sildenafil) Cialis (tadalafil) Levitra/Nuviva (vardenafil) Pipeline analysis Alibra (alprostadil + prazosin) Alprox-TD (alprostadil) Dapoxetine PNU-83757 Chapter 7 Osteoporosis Summary Disease overview Pathophysiology and etiology Epidemiology Methodological difficulties in assessing prevalence Prevalence of osteoporosis and osteopenia in post-menopausal women Prevalence of osteoporosis and osteopenia in men Market analysis Impact of the Women’s Health Initiative on osteoporosis therapy Leading and new product sales to 2008 Premarin family (conjugated estrogens) Fosamax (alendronate) Actonel (risedronate) Evista (raloxifene) Forteo (teriparatide) Pipeline analysis Boniva/Bondronat (ibandronate) Zometa (zoledronate) Lasofoxifene Premarin (conjugated estrogens) + bazedoxifene Chapter 8 Prostate cancer Summary Disease overview Epidemiology Market analysis Zoladex (goserelin) Casodex (bicalutamide) Lupron (leuprolide) Pipeline analysis Plenaxis (abarelix depot) Atrasentan Provenge (aberalix depot) Chapter 9 Appendix References Alzheimer’s disease Male sexual dysfunction Osteoporosis Prostate cancer Index List of Figures Figure 1.1: Average annual growth rates of the total population and the population in broad age groups, by major area, 2000-50 (median variant) Figure 1.2: The aging female population provides expanding opportunities in women’s health Figure 1.3: Healthcare spend increases with age Figure 1.4: Life expectancy at birth is rising Figure 1.5: Seniors visit physicians more frequently than their younger counterparts Figure 1.6: The rate of Internet uptake is greatest among seniors Figure 1.7: Online seniors are approaching physicians with information from the Internet Figure 1.8: Online seniors are searching for information on age-related diseases Figure 1.9: Novartis’ www.healthandage.com Figure 2.10: Incidence of ischemic stroke in the seven major markets, 2002 Figure 3.11: Prevalence of Alzheimer’s disease across the seven major markets, 2002 Figure 6.12: Prevalence of male sexual dysfunction, 2002 Figure 7.13: Prevalence of osteopenia and osteoporosis in the post-menopausal population across the seven major markets, 2002 Figure 7.14: Prevalence of osteopenia and osteoporosis in men aged 50+, 2002 Figure 8.15: Segmentation of prostate cancer patients among the seven major markets, 2003 List of Tables Table 2.1: Incidence of ischemic stroke in the seven major markets, 2002 Table 2.2: Antithrombotics in development for acute ischemic stroke, 2003 Table 3.3: Prevalence of Alzheimer’s disease across the seven major markets, 2002 Table 3.4: Leading and new Alzheimer’s disease product sales, 2001-08 Table 3.5: Late stage Alzheimer’s disease pipeline, 2003 Table 4.6: Leading and new arthritis product sales, 2001-08 Table 4.7: Late-stage arthritis pipeline, 2003 Table 5.8: Prevalence of diabetes in the seven major markets, 2002 Table 5.9: Leading and new diabetes product sales, 2001-08 Table 5.10: Non-invasive insulin pipeline, 2003 Table 6.11: Prevalence of male sexual dysfunction, 2002 (000s) Table 6.12: Prevalence of complete and severe erectile dysfunction in the over 40s, 2002 (000s) 135 Table 6.13: Global forecasts of leading and innovative erectile dysfunction drugs to 2008 Table 6.14: Male sexual dysfunction pipeline, phase II and above, 2003 Table 7.15: Prevalence of osteopenia and osteoporosis in the post-menopausal population across the seven major markets, 2002 Table 7.16: Prevalence of osteopenia and osteoporosis in men aged 50+, 2002 Table 7.17: Leading and new product sales in the osteoporosis market, 2002-08 Table 7.18: Osteoporosis pipeline, phase II and above, 2003 Table 8.19: Prevalence of prostate cancer in the seven major markets, 2003 Table 8.20: Leading prostate cancer product sales, 2001-08 Table 8.21: Late-stage prostate cancer pipeline, 2003 AbstractCommercial Opportunities from an Aging Population: Epidemiology market and pipeline analysis across seven major indications, evaluates the benefits of marketing to seniors for the pharmaceutical industry. Globally, the number of older people will increase from 606m in 2000 to 1.9bn in 2050 and as a result healthcare needs will increase and drugs will be used for longer. This report analyzes commercial opportunities within the ‘gray market’ and shows how companies can meet these needs and keep company profits high. Current and future growth prospects are examined for pharmaceutical companies to 2008 in seven major indications particularly associated with seniors. These are acute ischemic stroke, Alzheimer’s disease, arthritis, diabetes, male sexual dysfunction, osteoporosis and prostate cancer. Cumulatively, the total value of these markets was approximately $42bn in 2002 and this figure is set to rise dramatically.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||